Document Type
Article
Publication Date
2-21-2023
Abstract
Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive extranodal non-Hodgkin lymphoma (NHL) with poor outcomes, particularly in advanced-stage and relapsed/refractory disease. Emerging research on molecular drivers of ENKTL lymphomagenesis by next-generation and whole genome sequencing has revealed diverse genomic mutations in multiple signaling pathways, with the identification of multiple putative targets for novel therapeutic agents. In this review, we summarize the biological underpinnings of newly-understood therapeutic targets in ENKTL with a focus on translational implications, including epigenetic and histone regulatory aberrations, activation of cell proliferation signaling pathways, suppression of apoptosis and tumor suppressor genes, changes in the tumor microenvironment, and EBV-mediated oncogenesis. In addition, we highlight prognostic and predictive biomarkers which may enable a personalized medicine approach toward ENKTL therapy.
Recommended Citation
Major, Ajay; Porcu, Pierluigi; and Haverkos, Bradley M, "Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma" (2023). Department of Medical Oncology Faculty Papers. Paper 229.
https://jdc.jefferson.edu/medoncfp/229
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
36900160
Language
English
Comments
This article is the author’s final published version in Cancers, Volume 15, Issue 5, February 2023, Article number 1366.
The published version is available at https://doi.org/10.3390/cancers15051366. Copyright © Major et al.